Drug data last refreshed 15h ago
NOVAMINE 8.5% is an amino acid injection approved by Pfizer in 1978 for parenteral nutritional support in patients with muscle atrophy and pressure ulcers. It delivers essential amino acids intravenously to support protein synthesis and tissue repair in hospitalized or nutritionally compromised patients. The product functions as a nutritional therapeutic rather than a mechanistic drug.
Product is in late-stage maturity with LOE approaching; expect commercial teams to focus on defending market share against generic erosion and operational efficiency rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
The Effects of a Dialysis-Specific Formula Rich in Branched-Chain Amino Acids, Omega-3, and Dietary Fiber on Nutritional Status
Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)
The Glucagonotropic Effect of Amino Acids in Humans
Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU)
Bioavailability of Plant Protein Amino Acids
Worked on NOVAMINE 8.5% at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on NOVAMINE 8.5% in a LOE-approaching environment offers limited growth trajectory but provides solid experience in mature product management, institutional healthcare dynamics, and defensive commercial strategy. Pharma professionals on this team are more likely to optimize existing market position and manage transition to generic competition than to drive innovation or expansion.